Serum Biomarker gMS-Classifier2: Predicting Conversion to Clinically Definite Multiple Sclerosis

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Arrambide, Georgina ^a   Espejo, Carmen ^a   Yarden, Jennifer ^b   Fire, Ella ^b   Spector, Larissa ^b   Dotan, Nir ^b   Dukler, Avinoam ^b   Rovira, Alex ^a   Montalban, Xavier ^a   Tintore, Mar ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b Department of Research and Development Glycominds ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CLASSIFICATION ALGORITHM; CLINICALLY DEFINITE MULTIPLE SCLEROSIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PREDICTION; RISK ASSESSMENT;

ADULT; ALGORITHMS; AREA UNDER CURVE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DEMYELINATING DISEASES; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOGLOBULIN M; LONGITUDINAL STUDIES; MALE; MULTIPLE SCLEROSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; ROC CURVE; TIME FACTORS;

EID: 84875546148     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059953     Document Type: Article

References (37)

1. Tintoré M, Rovira A, Río J, Nos C, Grivé E, et al. (2006) Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 67: 968-972.
2. Fisniku LK, Brex PA, Altmann DR, Miszkiel KA, Benton CE, et al. (2008) Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 131: 808-817.
3. Sharief MK, Thompson EJ, (1991) The predictive value of intrathecal immunoglobulin synthesis and magnetic resonance imaging in acute isolated syndromes for subsequent development of multiple sclerosis. Ann Neurol 29: 147-151.
4. Frederiksen JL, Larsson HB, Olesen J, (1992) Correlation of magnetic resonance imaging and CSF findings in patients with acute monosymptomatic optic neuritis. Acta Neurol Scand 86: 317-322.
5. Tintoré M, Rovira A, Río J, Tur C, Pelayo R, et al. (2008) Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology 70: 1079-1083.
6. Arnold AC, (2005) Evolving management of optic neuritis and multiple sclerosis. Am J Ophthalmol 139: 1101-1108.
7. Tumani H, Hartung HP, Hemmer B, Teunissen C, Deisenhammer F, et al. (2009) Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis 35: 117-127.
8. van Kooyk Y, Rabinovich GA, (2008) Protein-glycan interactions in the control of innate and adaptive immune responses. Nat Immunol 9: 593-601.
9. Dzhambazov B, Nandakumar KS, Kihlberg J, Fugger L, Holmdahl R, et al. (2006) Therapeutic vaccination of active arthritis with a glycosylated collagen type II peptide in complex with MHC class II molecules. J Immunol 176: 1525-1533.
10. Chiba A, Kusunoki S, Shimizu T, Kanazawa I, (1992) Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol 31: 677-679.
11. Sendid B, Colombel JF, Jacquinot PM, Faille C, Fruit J, et al. (1996) Specific antibody response to oligomannosidic epitopes in Crohn's disease. Clin Diagn Lab Immunol 3: 219-226.
12. Rieder F, Schleder S, Wolf A, Dirmeier A, Strauch U, et al. (2010) Serum anti-glycan antibodies predict complicated Crohn's disease behavior: a cohort study. Inflamm Bowel Dis 16: 1367-1735.
13. Schwarz M, Spector L, Gortler M, Weisshaus O, Glass-Marmor L, et al. (2006) Serum anti-Glc(alpha1,4)Glc(alpha) antibodies as a biomarker for relapsing-remitting multiple sclerosis. J Neurol Sci 244: 59-68.
14. Freedman MS, Laks J, Dotan N, Altstock R, Dukler A, et al. (2009) Anti-alpha-glucose-based glycan IgM antibodies predict relapse activity in multiple sclerosis after the first neurological event. Mult Scler 15: 422-430.
15. Brettschneider J, Jaskowski TD, Tumani H, Abdul S, Husebye D, et al. (2009) Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases. J Neuroimmunol 217: 95-101.
16. Freedman M, Edan G, Hartung HP, Kappos L, Miller DH, et al. (2009) Anti-alpha-glucose based glycan IgM antibodies in patients with a clinically isolated syndrome: analyses from the Betaferon® in Newly Emerging multiple sclerosis For Initial Treatment (BENEFIT) study. Mult Scler. 15(suppl 2): S71.
17. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research proposals. Ann Neurol 13: 227-231.
18. Schwarz M, Spector L, Gargir A, Shtevi A, Gortler M, et al. (2003) A new kind of carbohydrate array, its use for profiling antiglycan antibodies, and the discovery of a novel human cellulose-binding antibody. Glycobiology 13: 749-754.
19. Yarden J, Dotan N, Fire E, L Spector, H Schmidt, et al. (2010) Positive serum values of gMS-Classifier2 associates with high relapse activity in relapsing-remitting multiple sclerosis patients. Mult Scler 16 (suppl (10) (): S187.
20. Frohman EM, Havrdova E, Lublin F, Barkhof F, Achiron A, et al. (2006) Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch Neurol 63: 614-619.
21. Río J, Comabella M, Montalban X, (2011) Multiple sclerosis: current treatment algorithms. Curr Opin Neurol 24: 230-237.
22. Fazekas F, Baumhackl U, Berger T, Deisenhammer F, Fuchs S, et al. (2010) Decision-making for and impact of early immunomodulatory treatment: the Austrian Clinically Isolated Syndrome Study (ACISS). Eur J Neurol 17: 852-860.
23. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, et al. (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69: 292-302.
24. Teunissen CE, Dijkstra C, Polman C, (2005) Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol 4: 32-41.
25. Pettenkofer HJ, Bickerich R, (1960) On common antigen properties between the human blood group ABO and the pathogen of diseases dangerous to the community. Zentralbl Bakteriol 179: 433-436.
26. Nimrichter L, Gargir A, Gortler M, Altstock RT, Shtevi A, et al. (2004) Intact cell adhesion to glycan microarrays. Glycobiology 14: 197-203.
27. Menge T, Lalive PH, von Büdingen HC, Cree B, Hauser SL, et al. (2005) Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis. J Allergy ClinImmunol 116: 453-459.
28. Lolli F, Mulinacci B, Carotenuto A, Bonetti B, Sabatino G, et al. (2005) An N-glucosylated peptide detecting disease-specific autoantibodies, biomarkers of multiple sclerosis. Proc Natl Acad Sci U S A 102: 10273-10278.
29. Lolli F, Mazzanti B, Pazzagli M, Peroni E, Alcaro MC, et al. (2005) The glycopeptide CSF114(Glc) detects serum antibodies in multiple sclerosis. J Neuroimmunol 167: 131-137.
30. van Horssen J, Bö L, Dijkstra CD, de Vries HE, (2006) Extensive extracellular matrix depositions in active multiple sclerosis lesions. Neurobiol Dis 24: 484-491.
31. Brettschneider J, Jaskowski TD, Tumani H, Abdul S, Husebye D, et al. (2009) Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases. J Neuroimmunol 217: 95-101.
32. Freedman M, Metzig C, Kappos L, Polman C, Edan G, et al. (2012) Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis. Mult Scler 18: 966-973.
33. Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O, Ledue TB, et al. (1998) Reference distributions for immunoglobulins A, G, and M: a practical, simple, and clinically relevant approach in a large cohort. J Clin Lab Anal 12: 363-370.
34. Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O, (1998) Reference distributions for immunoglobulins A, G, and M: a comparison of a large cohort to the world's literature. J Clin Lab Anal 12: 371-377.
35. Simel DL, Samsa GP, Matchar DB, (1993) Likelihood ratios for continuous test results-making the clinicians' job easier or harder? J Clin Epidemiol 46: 85-93.
36. Vickers AJ, Cronin AM, Begg CB, (2011) One statistical test is sufficient for assessing new predictive markers. BMC Med Res Methodol 11: 13.
37. Pepe MS, Kerr KF, Longton G, Wang Z (2013) Testing for improvement in prediction model performance. Stat Med Jan 7 [Epub ahead of print].